CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

Christophe Ginestier, Suling Liu, Mark E. Diebel, Hasan Korkaya, Ming Luo, Marty Brown, Julien Wicinski, Olivier Cabaud, Emmanuelle Charafe-Jauffret, Daniel Birnbaum, Jun Lin Guan, Gabriela Dontu, Max S. Wicha

Research output: Contribution to journalArticle

501 Citations (Scopus)

Abstract

Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. We report here the development of a strategy to target these breast cancer stem cells (CSCs) through blockade of the IL-8 receptor CXCR1. CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. Furthermore, this was followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling. The effects of CXCR1 blockade on CSC viability and on FASL production were mediated by the FAK/AKT/ FOXO3A pathway. In addition, repertaxin was able to specifically target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing metastasis. Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs.

Original languageEnglish (US)
Pages (from-to)485-497
Number of pages13
JournalJournal of Clinical Investigation
Volume120
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Neoplastic Stem Cells
Heterografts
Breast Neoplasms
Population
Interleukin-8 Receptors
Neoplasm Metastasis
Neoplasms
Blocking Antibodies
Cell Survival
In Vitro Techniques
Apoptosis
Cell Line
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. / Ginestier, Christophe; Liu, Suling; Diebel, Mark E.; Korkaya, Hasan; Luo, Ming; Brown, Marty; Wicinski, Julien; Cabaud, Olivier; Charafe-Jauffret, Emmanuelle; Birnbaum, Daniel; Guan, Jun Lin; Dontu, Gabriela; Wicha, Max S.

In: Journal of Clinical Investigation, Vol. 120, No. 2, 01.02.2010, p. 485-497.

Research output: Contribution to journalArticle

Ginestier, C, Liu, S, Diebel, ME, Korkaya, H, Luo, M, Brown, M, Wicinski, J, Cabaud, O, Charafe-Jauffret, E, Birnbaum, D, Guan, JL, Dontu, G & Wicha, MS 2010, 'CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts', Journal of Clinical Investigation, vol. 120, no. 2, pp. 485-497. https://doi.org/10.1172/JCI39397
Ginestier, Christophe ; Liu, Suling ; Diebel, Mark E. ; Korkaya, Hasan ; Luo, Ming ; Brown, Marty ; Wicinski, Julien ; Cabaud, Olivier ; Charafe-Jauffret, Emmanuelle ; Birnbaum, Daniel ; Guan, Jun Lin ; Dontu, Gabriela ; Wicha, Max S. / CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. In: Journal of Clinical Investigation. 2010 ; Vol. 120, No. 2. pp. 485-497.
@article{f11b4e3185624969a0e6aade7cfd6e0b,
title = "CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts",
abstract = "Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. We report here the development of a strategy to target these breast cancer stem cells (CSCs) through blockade of the IL-8 receptor CXCR1. CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. Furthermore, this was followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling. The effects of CXCR1 blockade on CSC viability and on FASL production were mediated by the FAK/AKT/ FOXO3A pathway. In addition, repertaxin was able to specifically target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing metastasis. Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs.",
author = "Christophe Ginestier and Suling Liu and Diebel, {Mark E.} and Hasan Korkaya and Ming Luo and Marty Brown and Julien Wicinski and Olivier Cabaud and Emmanuelle Charafe-Jauffret and Daniel Birnbaum and Guan, {Jun Lin} and Gabriela Dontu and Wicha, {Max S.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1172/JCI39397",
language = "English (US)",
volume = "120",
pages = "485--497",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

AU - Ginestier, Christophe

AU - Liu, Suling

AU - Diebel, Mark E.

AU - Korkaya, Hasan

AU - Luo, Ming

AU - Brown, Marty

AU - Wicinski, Julien

AU - Cabaud, Olivier

AU - Charafe-Jauffret, Emmanuelle

AU - Birnbaum, Daniel

AU - Guan, Jun Lin

AU - Dontu, Gabriela

AU - Wicha, Max S.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. We report here the development of a strategy to target these breast cancer stem cells (CSCs) through blockade of the IL-8 receptor CXCR1. CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. Furthermore, this was followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling. The effects of CXCR1 blockade on CSC viability and on FASL production were mediated by the FAK/AKT/ FOXO3A pathway. In addition, repertaxin was able to specifically target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing metastasis. Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs.

AB - Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. We report here the development of a strategy to target these breast cancer stem cells (CSCs) through blockade of the IL-8 receptor CXCR1. CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. Furthermore, this was followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling. The effects of CXCR1 blockade on CSC viability and on FASL production were mediated by the FAK/AKT/ FOXO3A pathway. In addition, repertaxin was able to specifically target the CSC population in human breast cancer xenografts, retarding tumor growth and reducing metastasis. Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs.

UR - http://www.scopus.com/inward/record.url?scp=76649113726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649113726&partnerID=8YFLogxK

U2 - 10.1172/JCI39397

DO - 10.1172/JCI39397

M3 - Article

C2 - 20051626

AN - SCOPUS:76649113726

VL - 120

SP - 485

EP - 497

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -